Edgar Filing: JOHNSON & JOHNSON

tenq3rdqtr2008.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 28, 2008

( ) Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to

Commission file number 1-3215

(Exact name of registrant as specified in its charter)

NEW JERSEY

(State or other jurisdiction of

incorporation or organization)

22-1024240

(I.R.S. Employer

Identification No.)

One Johnson & Johnson Plaza

New Brunswick, New Jersey 08933

(Address of principal executive offices)

Registrant's telephone number, including area code (732) 524-0400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (X) Yes ( )No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer (X)Accelerated filer ( ) Non-accelerated filer ( ) Smaller reporting company ( )

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).( ) Yes(X) No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On October 26, 2008 2,774,568,107 shares of Common Stock, $1.00 par value, were outstanding.

JOHNSON & JOHNSON AND SUBSIDIARIES

TABLE OF CONTENTS

Part I - Financial Information	Page No.

Item 1. Financial Statements (unaudited)

Consolidated Balance Sheets - September 28, 2008 and December 30, 2007	3

Consolidated Statements of Earnings for the Fiscal Third Quarters Ended September 28, 2008 and September 30, 2007	5

Consolidated Statements of Earnings for the Fiscal Nine Months Ended September 28, 2008 and September 30, 2007	6

Consolidated Statements of Cash Flows for the Fiscal Nine Months Ended September 28, 2008 and September 30, 2007	7

Notes to Consolidated Financial Statements	9

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	33

Item 3. Quantitative and Qualitative Disclosures About Market Risk	46

Item 4. Controls and Procedures	46

Part II - Other Information

Item 1 - Legal Proceedings	47

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	47

Item 6 - Exhibits	48

Signatures	49

Part I - FINANCIAL INFORMATION

Item 1 – FINANCIAL STATEMENTS

JOHNSON & JOHNSON AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited; Dollars in Millions)

ASSETS

	September 28, 2008			December 30, 2007
Current assets:
Cash & cash equivalents	$	14,018		$	7,770
Marketable securities		781			1,545
Accounts receivable, trade, less allowances for doubtful accounts $254 (2007,$193)		10,156			9,444
Inventories (Note 4)		5,473			5,110
Deferred taxes on income		2,584			2,609
Prepaid expenses and other receivables		3,578			3,467
Total current assets		36,590			29,945
Marketable securities, non-current		2			2
Property, plant and equipment at cost		27,601			26,466
Less: accumulated depreciation		(13,246	)		(12,281	)
Property, plant and equipment, net		14,355			14,185
Intangible assets, net (Note 5)		14,296			14,640
Goodwill, net (Note 5)		14,275			14,123
Deferred taxes on income		5,191			4,889
Other assets		3,015			3,170
Total assets	$	87,724		$	80,954

See Notes to Consolidated Financial Statements

JOHNSON & JOHNSON AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited; Dollars in Millions)

LIABILITIES AND SHAREHOLDERS' EQUITY

	September 28, 2008			December 30, 2007
Current liabilities:
Loans and notes payable	$	6,245		$	2,463
Accounts payable		6,384			6,909
Accrued liabilities		5,521			6,412
Accrued rebates, returns and promotions		2,609			2,318
Accrued salaries, wages and commissions		1,513			1,512
Accrued taxes on income		458			223
Total current liabilities		22,730			19,837
Long-term debt		8,395			7,074
Deferred taxes on income		1,384			1,493
Employee related obligations		5,533			5,402
Other liabilities		3,948			3,829
Total liabilities		41,990			37,635
Shareholders’ equity:
Common stock – par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,842,548 shares)		3,120			3,120
Accumulated other comprehensive income (Note 8)		(930	)		(693	)
Retained earnings		61,878			55,280
Less: common stock held in treasury, at cost (339,515,000 and 279,620,000 shares)		18,334			14,388
Total shareholders’ equity		45,734			43,319
Total liabilities and shareholders’ equity	$	87,724		$	80,954

See Notes to Consolidated Financial Statements

JOHNSON & JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

(Unaudited; dollars & shares in millions

except per share amounts)

	Fiscal Quarters Ended
	Sept. 28, 2008			Percent to Sales			Sept. 30, 2007			Percent to Sales
Sales to customers (Note 6)	$	15,921			100.0	%	$	14,970			100.0	%
Cost of products sold		4,774			30.0			4,274			28.5
Gross profit		11,147			70.0			10,696			71.5
Selling, marketing and administrative expenses		5,195			32.6			4,899			32.7
Research expense		1,861			11.7			1,834			12.3
Restructuring (Note 11)		-			-			745			5.0
Interest income		(97	)		(0.6	)		(134	)		(0.9	)
Interest expense, net of portion capitalized		122			0.8			82			0.6
Other (income)expense, net		(224	)		(1.4	)		2			-
Earnings before provision for taxes on income		4,290			26.9			3,268			21.8
Provision for taxes on income (Note 3)		980			6.1			720			4.8
NET EARNINGS	$	3,310			20.8	%	$	2,548			17.0	%
` NET EARNINGS PER SHARE (Note 7)
Basic	$	1.19					$	0.88
Diluted	$	1.17					$	0.88
CASH DIVIDENDS PER SHARE	$	0.460					$	0.415
AVG. SHARES OUTSTANDING
Basic		2,790.9						2,887.7
Diluted		2,831.3						2,912.9

See Notes to Consolidated Financial Statements

JOHNSON & JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

(Unaudited; dollars & shares in millions

except per share amounts)

	Fiscal Nine Months Ended
	Sept. 28, 2008			Percent to Sales			Sept. 30, 2007			Percent to Sales
Sales to customers (Note 6)	$	48,565			100.0	%	$	45,138			100.0	%
Cost of products sold		14,139			29.1			13,017			28.8
Gross profit		34,426			70.9			32,121			71.2
Selling, marketing and administrative expenses		15,825			32.6			14,730			32.6
Research expense		5,469			11.3			5,352			11.9
In-process research & development (IPR&D)		40			0.1			807			1.8
Restructuring (Note 11)		-			-			745			1.7
Interest income		(268	)		(0.6	)		(324	)		(0.7	)
Interest expense, net of portion capitalized		325			0.7			203			0.4
Other (income)expense, net		(377	)		(0.8	)		(343	)		(0.8	)
Earnings before provision for taxes on income		13,412			27.6			10,951			24.3
Provision for taxes on income (Note 3)		3,177			6.5			2,749			6.1
NET EARNINGS	$	10,235			21.1	%	$	8,202			18.2	%
NET EARNINGS PER SHARE (Note 7)
Basic	$	3.64					$	2.84
Diluted	$	3.60					$	2.81
CASH DIVIDENDS PER SHARE	$	1.335					$	1.205
AVG. SHARES OUTSTANDING
Basic		2,811.9						2,892.0
Diluted		2,847.8						2,919.3

See Notes to Consolidated Financial Statements

JOHNSON & JOHNSON AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; Dollars in Millions)

	Fiscal Nine Months Ended
	Sept. 28, 2008			Sept. 30, 2007
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings	$	10,235		$	8,202
Adjustment to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles		2,117			1,902
Stock based compensation		524			537
Purchased in-process research and development		40			807
Deferred tax provision		(354	)		(900	)
Accounts receivable allowances		62			13
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable		(790	)		(407	)
Increase in inventories		(348	)		(309	)
(Decrease)/Increase in accounts payable and accrued liabilities		(1,103	)		933
Increase in other current and non-current assets		(2	)		(1,007	)
Increase in other current and non-current liabilities		590			1,154
NET CASH FLOWS FROM OPERATING ACTIVITIES		10,971			10,925
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment		(1,938	)		(1,704	)
Proceeds from the disposal of assets		56			214
Acquisitions, net of cash acquired		(400	)		(1,378	)
Purchases of investments		(1,434	)		(8,475	)
Sales of investments		2,079			6,706
Other (primarily intangibles)		(36	)		(101	)
NET CASH USED BY INVESTING ACTIVITIES		(1,673	)		(4,738	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders		(3,750	)		(3,486	)
Repurchase of common stock		(5,773	)		(2,581	)
Proceeds from short-term debt		5,194			20,124
Retirement of short-term debt		(1,649	)		(21,461	)
Proceeds from long-term debt		1,640			2,605
Retirement of long-term debt		(16	)		(12	)
Proceeds from the exercise of stock options/excess tax benefits		1,360			961

NET CASH USED BY FINANCING ACTIVITIES		(2,994	)		(3,850	)

Effect of exchange rate changes on cash and cash equivalents		(56	)		220
Increase/(decrease) in cash and cash equivalents		6,248			2,557
Cash and Cash equivalents, beginning of period		7,770			4,083
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	14,018		$	6,640



Acquisitions
Fair value of assets acquired	$	416		$	1,609
Fair value of liabilities assumed		(16	)		(231	)
Net cash paid for acquisitions	$	400		$	1,378

See Notes to Consolidated Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its Subsidiaries (the "Company") and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2007. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

During the fiscal first quarter of 2008, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This statement was adopted in the fiscal first quarter of 2008 except for non-financial assets and liabilities recognized or disclosed at fair value on a non-recurring basis, for which the effective date is fiscal years beginning after November 15, 2008. See Note 13 for more details.

During the fiscal first quarter of 2008, the Company adopted SFAS No. 159, Fair Value Option for Financial Assets and Financial Liabilities, which permits an entity to measure financial assets and financial liabilities at fair value. See Note 13 for more details.

During the fiscal first quarter of 2008, the Company adopted EITF Issue 07-03 Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities. This issue requires nonrefundable advance payments for research and development to be capitalized and recognized as an expense as related goods are delivered or services are performed. The adoption of EITF Issue 07-03 did not have a significant impact on the Company’s results of operation, cash flows or financial position.

NOTE 2 - FINANCIAL INSTRUMENTS

The Company follows the provisions of Statement of Financial Accounting Standards (SFAS) 133, SFAS 138 and SFAS 149 requiring that all derivative instruments be recorded on the balance sheet at fair value.

As of September 28, 2008, the balance of deferred net gains on derivatives included in accumulated other comprehensive income was $64 million after-tax. For additional information, see Note 8. The Company expects that substantially all of this amount will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The amount ultimately realized in earnings will differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. Transactions with third parties will cause the amount in accumulated other comprehensive income to affect net earnings. The length of time over which the Company is hedging typically does not exceed 18 months. The Company also uses currency swaps to manage currency risk primarily related to borrowings, which may exceed 18 months.

For the fiscal third quarters ended September 28, 2008 and September 30, 2007, the net impact of the hedges' ineffectiveness, transactions not qualifying for hedge accounting and discontinuance of hedges, to the Company's financial statements was insignificant. Refer to Note 8 for disclosures of movements in Accumulated Other Comprehensive Income.

NOTE 3 - INCOME TAXES

The worldwide effective income tax rates for the first fiscal nine months of 2008 and 2007 were 23.7% and 25.1%, respectively. The decrease in the effective tax rate was primarily due to the lower in-process research and development (IPR&D) charge of $40 million with no tax benefit recorded in the first fiscal nine months of 2008 versus the IPR&D charge of $807 million with no tax benefit recorded in the first fiscal nine months of 2007. This benefit is reduced by higher taxes in 2008 due to the expiration of the Research and Development (R&D) credit at the end of 2007. The R&D credit was extended as part of the Emergency Economic Stabilization Act of 2008, signed in October of 2008 but is not included in the results of the first fiscal nine months of 2008.

NOTE 4 - INVENTORIES

(Dollars in Millions)

	September 28, 2008		December 30, 2007
Raw materials and supplies	$	943	$	905
Goods in process		1,655		1,384
Finished goods		2,875		2,821
Total	$	5,473	$	5,110

NOTE 5 - INTANGIBLE ASSETS AND GOODWILL

Intangible assets that have finite useful lives are amortized over their estimated useful lives. Goodwill and indefinite lived intangible assets are assessed annually for impairment. The latest impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2007. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted.

(Dollars in Millions)	September 28, 2008		December 30, 2007
Trademarks (non-amortizable)	$	6,223	$	6,457
Less accumulated amortization		147		144
Trademarks (non-amortizable)- net		6,076		6,313
Patents and trademarks		4,746		4,597
Less accumulated amortization		1,758		1,615
Patents and trademarks – net		2,988		2,982
Other amortizable intangibles		7,594		7,399
Less accumulated amortization		2,362		2,054
Other intangibles – net		5,232		5,345
Total intangible assets - gross		18,563		18,453
Less accumulated amortization		4,267		3,813
Total intangible assets - net		14,296		14,640
Goodwill – gross		15,014		14,866
Less accumulated amortization		739		743
Goodwill – net	$	14,275	$	14,123

Goodwill as of September 28, 2008 as allocated by segment of business is as follows:

(Dollars in Millions)	Consumer			Pharm		Med Dev & Diag		Total
Goodwill, net of accumulated amortization at December 30, 2007	$	8,125		$	964	$	5,034	$	14,123
Acquisitions		190			-		6		196
Translation & Other		(61	)		11		6		(44	)
Goodwill, net as of September 28, 2008	$	8,254		$	975	$	5,046	$	14,275

The weighted average amortization periods for patents and trademarks and other intangible assets are 16 years and 28 years, respectively. The amortization expense of amortizable intangible assets for the fiscal nine months ended September 28, 2008 was $593 million and the estimated amortization expense for the five succeeding years approximates $750 million, per year.

NOTE 6 - SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

(Dollars in Millions)

SALES BY SEGMENT OF BUSINESS (1)

	Fiscal Quarters Ended
(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Percent Change
Consumer
U.S.	$	1,769	$	1,591		11.2	%
International		2,330		2,032		14.7
Total		4,099		3,623		13.1
Pharmaceutical
U.S.		3,538		3,765		(6.0	)
International		2,575		2,334		10.3
Total		6,113		6,099		0.2
Medical Devices & Diagnostics
U.S.		2,648		2,569		3.1
International		3,061		2,679		14.3
Total		5,709		5,248		8.8
Worldwide
U.S.		7,955		7,925		0.4
International		7,966		7,045		13.1
Total	$	15,921	$	14,970		6.4	%

	Fiscal Nine Months Ended
(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Percent Change
Consumer
U.S.	$	5,282	$	4,782		10.5	%
International		6,917		5,901		17.2
Total		12,199		10,683		14.2
Pharmaceutical
U.S.		11,401		11,659		(2.2	)
International		7,481		6,810		9.9
Total		18,882		18,469		2.2
Medical Devices & Diagnostics
U.S.		7,959		7,772		2.4
International		9,525		8,214		16.0
Total		17,484		15,986		9.4
Worldwide
U.S.		24,642		24,213		1.8
International		23,923		20,925		14.3
Total	$	48,565	$	45,138		7.6	%

(1) Export sales are not significant.

OPERATING PROFIT BY SEGMENT OF BUSINESS

	Fiscal Quarters Ended
(Dollars in Millions)	Sept. 28, 2008			Sept. 30, 2007			Percent Change
Consumer (1)	$	764		$	586			30.4	%
Pharmaceutical (2)		2,003			1,594			25.7
Medical Devices & Diagnostics (3)		1,657			1,140			45.4
Segments total		4,424			3,320			33.3
Expense not allocated to segments (4)		(134	)		(52	)
Worldwide total	$	4,290		$	3,268			31.3	%

	Fiscal Nine Months Ended
(Dollars in Millions)	Sept. 28, 2008			Sept.30, 2007			Percent Change
Consumer (1)	$	2,175		$	1,828			19.0	%
Pharmaceutical (2)		6,513			6,006			8.4
Medical Devices & Diagnostics(3)(5)		5,159			3,378			52.7
Segments total		13,847			11,212			23.5
Expense not allocated to segments (4)		(435	)		(261	)
Worldwide total	$	13,412		$	10,951			22.5	%

(1) Includes restructuring charges of $15 million recorded in the fiscal third quarter and the first fiscal nine months of 2007.

(2) Includes restructuring charges of $429 million recorded in the fiscal third quarter and the first fiscal nine months of 2007.

(3) Includes restructuring charges of $301 million recorded in the fiscal third quarter and the first fiscal nine months of 2007.

(4) Amounts not allocated to segments include interest income/(expense), minority interest and general corporate income/(expense).

(5) Includes $40 million and $807 million of IPR&D charges related to acquisitions completed in the first fiscal nine months of 2008 and first fiscal nine months of 2007, respectively.

SALES BY GEOGRAPHIC AREA

(Dollars in Millions)

	Fiscal Quarters Ended
(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Percent Change
U.S.	$	7,955	$	7,925		0.4	%
Europe		4,076		3,765		8.3
Western Hemisphere, excluding U.S.		1,461		1,195		22.3
Asia-Pacific, Africa		2,429		2,085		16.5
Total	$	15,921	$	14,970		6.4	%

	Fiscal Nine Months Ended
(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Percent Change
U.S.	$	24,642	$	24,213		1.8	%
Europe		12,931		11,485		12.6
Western Hemisphere, excluding U.S.		3,986		3,372		18.2
Asia-Pacific, Africa		7,006		6,068		15.5
Total	$	48,565	$	45,138		7.6	%

NOTE 7 - EARNINGS PER SHARE

The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters ended September 28, 2008 and September 30, 2007.

(Shares in Millions)	Fiscal Quarters Ended
	Sept. 28, 2008			Sept. 30, 2007
Basic net earnings per share	$	1.19		$	0.88
Average shares outstanding – basic		2,790.9			2,887.7
Potential shares exercisable under stock option plans		242.0			192.0
Less: shares which could be repurchased under treasury stock method		(205.3	)		(170.6	)
Convertible debt shares		3.7			3.8
Average shares outstanding – diluted		2,831.3			2,912.9
Diluted earnings per share	$	1.17		$	0.88

The diluted earnings per share calculation included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $1 million for both the fiscal third quarters ended September 28, 2008 and September 30, 2007.

The diluted earnings per share calculation for the fiscal third quarter ended September 30, 2007, excluded 66 million shares related to stock options as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. For the fiscal third quarter ended September 28, 2008 the number of shares related to stock options for which the exercise price of these options was greater than their average market value was insignificant.

The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal nine months ended September 28, 2008 and September 30, 2007.

(Shares in Millions)	Fiscal Nine Months Ended
	Sept. 28, 2008			Sept. 30, 2007
Basic net earnings per share	$	3.64		$	2.84
Average shares outstanding – basic		2,811.9			2,892.0
Potential shares exercisable under stock option plans		241.5			192.3
Less: shares which could be repurchased under treasury stock method		(209.3	)		(168.8	)
Convertible debt shares		3.7			3.8
Average shares outstanding – diluted		2,847.8			2,919.3
Diluted earnings per share	$	3.60		$	2.81

The diluted earnings per share calculation included the dilutive effect of convertible debt that was offset by the related reduction in interest expense of $3 million for both the fiscal nine months ended September 28, 2008 and September 30, 2007.

The diluted earnings per share calculation for the first fiscal nine months ended September 28, 2008 and September 30, 2007, excluded 1 million and 65 million shares, respectively, related to stock options as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share.

NOTE 8 - ACCUMULATED OTHER COMPREHENSIVE INCOME

Total comprehensive income for the first fiscal nine months ended September 28, 2008 was $10.0 billion, compared with $8.8 billion for the same period a year ago. Total comprehensive income for the fiscal third quarter ended September 28, 2008 was $1.8 billion, compared with $2.9 billion for the same period a year ago. Total comprehensive income included net earnings, net unrealized currency gains and losses on translation, adjustments related to Employee Benefit Plans, net unrealized gains and losses on securities available for sale and net gains and losses on derivative instruments qualifying and designated as cash flow hedges. The following table sets forth the components of accumulated other comprehensive income.

(Dollars in Millions)	For. Cur. Trans.			Unrld Gains/ (Losses) on Sec			Employee Benefit Plans			Gains/(Losses) on Deriv & Hedges		Total Accum Other Comp Inc/(Loss)
December 30, 2007	$	628			84			(1,360	)	(45	)		(693	)
2008 nine months changes
Net change associated with current period hedging transactions										4
Net amount reclassed to net earnings										105	*
Net nine months changes		(406	)		(47	)		107		109			(237	)
September 28, 2008	$	222			37			(1,253	)	64			(930	)

Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation adjustments are not currently adjusted for income taxes, as they relate to permanent investments in international subsidiaries.

*Substantially offset in net earnings by changes in value of the underlying transactions.

NOTE 9 – MERGERS, ACQUISITIONS AND DIVESTITURES

During the fiscal third quarter of 2008 the Company acquired Beijing Dabao Cosmetics Co., Ltd., a company that sells personal care brands in China.

During the fiscal third quarter of 2008 the Company entered into a definitive agreement to sell Ethicon’s Professional Wound Care business. The divestiture is expected to close in the fiscal fourth quarter of 2008.

During the fiscal second quarter of 2008 the Company acquired Amic AB, a Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings (outside the physical facilities of the clinical laboratory). An in-process research & development (IPR&D) charge of $40 million before and after tax was recorded related to the acquisition of Amic AB.

During the fiscal first quarter of 2007, the Company acquired Conor Medsystems, Inc. for a purchase price of $1.4 billion in cash. Conor Medsystems, Inc., is a cardiovascular device company, with new drug delivery technology. An IPR&D charge of $807 million before and after tax was recorded related to the acquisition of Conor Medsystems, Inc.

During the fiscal first quarter of 2007, the Company completed the divestiture of the KAOPECTATE®, UNISOM®, CORTIZONE®, BALMEX® and ACT® consumer products to Chattem, Inc. for $410 million in cash.

NOTE 10 – PENSIONS AND OTHER POSTRETIREMENT BENEFITS

Components of Net Periodic Benefit Cost

Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters of 2008 and 2007 include the following components:

	Retirement Plans						Other Benefit Plans
	Fiscal Quarters Ended
(Dollars in Millions)	Sept. 28, 2008			Sept. 30, 2007			Sept. 28, 2008			Sept. 30, 2007
Service cost	$	126			148			35			34
Interest cost		177			169			43			37
Expected return on plan assets		(220	)		(208	)		(1	)		(1	)
Amortization of prior service cost		2			2			(1	)		(1	)
Amortization of net transition asset		-			1			-			-
Recognized actuarial losses		16			47			15			17
Curtailments and settlements		-			(2	)		-			-

Net periodic benefit cost	$	101			157			91			86

Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the first fiscal nine months of 2008 and 2007 include the following components:

	Retirement Plans						Other Benefit Plans
	Fiscal Nine Months Ended
(Dollars in Millions)	Sept. 28, 2008			Sept. 30, 2007			Sept. 28, 2008			Sept. 30, 2007
Service cost	$	381			417			106			104
Interest cost		534			489			126			111
Expected return on plan assets		(666	)		(603	)		(2	)		(2	)
Amortization of prior service cost		8			7			(4	)		(4	)
Amortization of net transition asset		1			1			-			-
Recognized actuarial losses		47			142			48			50
Curtailments and settlements		4			(2	)		-			-

Net periodic benefit cost	$	309			451			274			259

Company Contributions

For the fiscal nine months ended September 28, 2008, the Company contributed $21 million and $17 million to its U.S. and international retirement plans, respectively. The Company is not required to fund the U.S. retirement plans due to minimum statutory funding requirements for its U.S. retirement plans in 2008. Additional contributions may be made when deemed appropriate. International plans are funded in accordance with local regulations.

NOTE 11 – RESTRUCTURING

In the third quarter of 2007, the Company announced restructuring initiatives in an effort to improve its overall cost structure. This action was taken to offset the anticipated negative impacts associated with generic competition in the Pharmaceutical segment and challenges in the drug-eluting stent market. The Company's Pharmaceuticals segment is reducing its cost base by consolidating certain operations, while continuing to invest in recently launched products and its late-stage pipeline of new products. The Cordis franchise is moving to a more integrated business model to address the market changes underway with drug-eluting stents and to better serve the broad spectrum of its patients' cardiovascular needs, while reducing its cost base. Additionally, as part of this initiative the Company plans to eliminate approximately 4,400 positions of which 3,300 have been eliminated since this restructuring initiative was announced. The Company is also accelerating steps to standardize and streamline certain aspects of its enterprise-wide functions such as human resources, finance and information technology to support growth across the business, while also leveraging its scale more effectively in areas such as procurement to benefit its operating companies.

During the fiscal third quarter of 2007, the Company recorded $745 million in pre-tax charges of which, approximately, $500 million of the pre-tax restructuring charges are expected to require cash payments. The $745 million of restructuring charges consists of severance costs of $450 million, asset write-offs of $272 million and $23 million related to leasehold obligations. The $272 million of asset write-offs relate to property, plant and equipment of $166 million, intangible assets of $48 million and other assets of $58 million.

The following table summarizes the severance reserve and the associated spending under this initiative through the third quarter of 2008:

(Dollars in Millions)

Reserve balance as of:

December 30, 2007

Cash outlays*

September 28, 2008

Severance

$404

(195)

$209

*Cash outlays for severance are expected to be substantially paid out over the next 9-12 months in accordance with the Company’s plans and local laws.

NOTE 12 - LEGAL PROCEEDINGS

PRODUCT LIABILITY

The Company is involved in numerous product liability cases in the United States, many of which concern adverse reactions to drugs and medical devices. The damages claimed are substantial, and while the Company is confident of the adequacy of the warnings and instructions for use that accompany such products, it is not feasible to predict the ultimate outcome of litigation. However, the Company believes that if any product liability results from such cases, it will be substantially covered by existing amounts accrued in the Company’s balance sheet and, where available, by third-party product liability insurance.

Multiple products of Johnson & Johnson subsidiaries are subject to numerous product liability claims and lawsuits, including ORTHO EVRA®, RISPERDAL®, DURAGESIC® and the CHARITÉ™ Artificial Disc. There are approximately 1,200 claimants who have pending lawsuits or claims regarding injuries allegedly due to ORTHO EVRA®, 535 with respect to RISPERDAL®, 288 with respect to CHARITÉ™ and 100 with respect to DURAGESIC®. These claimants seek substantial compensatory and, where available, punitive damages.

With respect to RISPERDAL®, the Attorneys General of eight states and the Office of General Counsel of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other public funds for RISPERDAL® prescriptions written for off-label use, compensation for treating their citizens for alleged adverse reactions to RISPERDAL®, civil fines or penalties, punitive damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state seeking similar relief. Certain of these actions also seek injunctive relief relating to the promotion of RISPERDAL®. The Attorneys General of more than 40 other states have indicated a potential interest in pursuing similar litigation against the Company’s Janssen subsidiary, and have obtained a tolling agreement staying the running of the statute of limitations while they inquire into the issues. In addition, there are six cases filed by union health plans seeking damages for alleged overpayments for RISPERDAL®, several of which seek certification as class actions. In the case brought by the Attorney General of West Virginia, based on claims for alleged consumer fraud as to DURAGESIC® as well as RISPERDAL®, Janssen was found liable on motion, and damages are likely to be assessed at less than $20 million. Janssen intends to appeal.

Numerous claims and lawsuits in the United States relating to the drug PROPULSID®, withdrawn from general sale by the Company’s Janssen subsidiary in 2000, have been resolved or are currently enrolled in settlement programs with an aggregate cap below $100 million. Litigation concerning PROPULSID® is pending in Canada, where a class action of persons alleging adverse reactions to the drug has been certified.

AFFIRMATIVE STENT PATENT LITIGATION

In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis Corporation (Cordis), a subsidiary of Johnson & Johnson, obtained verdicts of infringement and patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December 2000, the jury in the damage action against Boston Scientific returned a verdict of $324 million and the jury in the Medtronic action returned a verdict of $271 million. The Court of Appeals for the Federal Circuit has upheld liability in these cases, and on September 30, 2008, the district court entered judgments, including interest, in the amounts of $702 million and $521 million against Boston Scientific and Medtronic, respectively. Boston Scientific has appealed the judgment, but Medtronic paid $472 million in October 2008, representing the judgment, net of amounts exchanged in settlement of a number of other litigations between the companies.

Cordis also has two arbitrations against Medtronic seeking royalties for the sale of stent products introduced by Medtronic subsequent to December 2000 pursuant to a 1997 cross-license agreement between Cordis and Medtronic. The hearing on the first of these arbitrations will take place in March 2009.

In January 2003, Cordis filed a patent infringement action against Boston Scientific in Delaware Federal District Court accusing its Express2™, Taxus® and Liberte® stents of infringing the Palmaz patent that expired in November 2005. The Liberte® stent was also accused of infringing Cordis’ Gray patent that expires in 2016. In June 2005, a jury found that the Express2™, Taxus® and Liberte® stents infringed the Palmaz patent and that the Liberte® stent also infringed the Gray patent. Boston Scientific has appealed to the U.S. Court of Appeals for the Federal Circuit.

Cordis has filed several lawsuits in New Jersey Federal District Court against Guidant Corporation, Abbott Laboratories, Inc., Boston Scientific and Medtronic alleging that the Xience V™ (Abbott), Promus™ (Boston Scientific) and Endeavor® (Medtronic) drug eluting stents infringe several patents owned by or licensed to Cordis. In October 2008, Cordis filed suit against Boston Scientific in Delaware Federal Court accusing the Taxus® Liberte® stent of infringing the Gray patent.

PATENT LITIGATION AGAINST VARIOUS JOHNSON & JOHNSON SUBSIDIARIES

The products of various Johnson & Johnson subsidiaries are the subject of various patent lawsuits, the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell those products, or require the payment of past damages and future royalties.

In July 2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER® Stent infringed Boston Scientific’s Ding ’536 patent and that the Cordis CYPHER® and BX VELOCITY® Stents also infringed Boston Scientific’s Jang ’021 patent. The jury also found both of those patents valid. Boston Scientific seeks substantial damages and an injunction in that action. The District Court denied motions by Cordis to overturn the jury verdicts or grant a new trial. Cordis has appealed to the Court of Appeals for the Federal Circuit. The District Court indicated it will consider damages, willfulness and injunctive relief after the appeals have been decided.

Boston Scientific has brought actions in Belgium, the Netherlands, Germany, France and Italy under its Kastenhofer patent, which purports to cover two-layer catheters such as those used to deliver the CYPHER® Stent, to enjoin the manufacture and sale of allegedly infringing catheters in those countries, and to recover damages. A decision by the lower court in the Netherlands in Boston Scientific’s favor was reversed on appeal in April 2007. Boston Scientific has filed an appeal to the Dutch Supreme Court. In October 2007, Boston Scientific prevailed in the nullity action challenging the validity of the Kastenhofer patent filed by Cordis in Germany. Cordis has appealed. No substantive hearings have been scheduled in the French or Italian actions.

Trial in Boston Scientific’s U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October 2007 with a jury finding that the patent was invalid. The jury also found for Cordis on its counterclaim that sale by Boston Scientific of its balloon catheters and stent delivery systems infringe Cordis’ Fontirroche patent. The Court has denied Boston Scientific’s post trial motions and is considering the appropriate remedy for future infringement.

In Germany, Boston Scientific has several actions based on its Ding patents pending against the Cordis CYPHER® Stent. Cordis was successful in these actions at the trial level, but Boston Scientific has appealed.

The following chart summarizes various patent lawsuits concerning products of Johnson & Johnson subsidiaries that have yet to proceed to trial:

J&J Product

Company

Patents

Plaintiff/Patent Holder

Court

Trial Date

Date Filed

Two-layer Catheters

Cordis

Kasten-hofer

Boston Scientific Corp.

Multiple European

09/07

Contact Lenses

Vision Care

Nicolson

CIBA Vision

M.D.FL

Multiple European

03/09

09/03

CYPHER® Stent

Cordis

Wall

E.D. TX

11/07

CYPHER® Stent

Cordis

Bonutti

MarcTec

S.D. IL

11/07

CYPHER® Stent

Cordis

Saffran

E.D. TX

10/07

Stent/Catheter

Delivery Systems

Cordis/ Ethicon

Schock

Cardio Access LLC

E.D. TX

06/08

LISTERINE® Tooth Whitening Strips

McNeil-PPC

Sagel

Procter & Gamble

W.D. WI

05/08

Blood Glucose Meters and Strips

Lifescan

Wilsey

Roche Diagnostics

D. DE

11/07

* Trial date to be scheduled.

LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

The following chart indicates lawsuits pending against generic firms that filed Abbreviated New Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of these patents. In the event the subsidiary of the Company involved is not successful in these actions, or the statutory 30-month stay expires before a ruling from the district court is obtained, the firms involved will have the ability, upon FDA approval, to introduce generic versions of the product at issue resulting in very substantial market share and revenue losses for the product of the Company’s subsidiary.

As noted in the following chart, 30-month stays expired during 2006 and 2007, and will expire in 2008, 2009, 2010 and 2011 with respect to ANDA challenges regarding various products:

Brand Name Product

Patent/NDA Holder

Generic Challenger

Court

Trial Date

Date Filed

30-Month Stay Expiration

CONCERTA®

McNeil-PPC

Andrx

D. DE

12/07

09/05

None

18,27,36 and 54 mg controlled release tablet

ALZA

LEVAQUIN® 250, 500, 750 mg tablets

Ortho-McNeil

Lupin

D. NJ

10/06

03/09

ORTHO TRI CYCLEN® LO

Ortho-McNeil

Barr

D. NJ

10/03

02/06

0.18 mg/0.025 mg

0.215 mg/0.025 mg and

0.25 mg/0.025 mg

Watson

D. NJ

10/08

03/11

RAZADYNE(TM)

Janssen

Teva

D. DE

05/07

07/05

08/08

Mylan

D. DE

05/07

07/05

08/08

Dr. Reddy's

D. DE

05/07

07/05

08/08

Purepac

D. DE

05/07

07/05

08/08

Barr

D. DE

05/07

07/05

08/08

AlphaPharm

D. DE

05/07

07/05

08/08

Sandoz

D. DE

08/08

None

RAZADYNE™ ER

Janssen

Barr

D. NJ

06/06

None

Sandoz

D. NJ

05/07

None

KV Pharma

D. NJ

12/07

05/10

ULTRACET

Ortho-McNeil

Apotex

N.D. IL

07/07

12/09

ULTRAM ER®

100, 200, 300 mg tablet

Ortho-McNeil

Par

D. DE

01/09

05/07

09/09

ULTRAM ER®

100 mg tablet

Ortho-McNeil-Janssen

Impax

D. DE

08/08

01/11

* Trial date to be scheduled.

In the action against Barr regarding ORTHO TRICYCLEN® LO, on January 22, 2008, the Company’s subsidiary Ortho Women’s Health & Urology, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Barr agreed to a non-binding term sheet to settle the litigation, which settlement discussions are still underway. The trial court postponed the January 22, 2008 trial without setting a new trial date.

On October 16, 2008, the Company’s subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) filed suit in Federal District Court in New Jersey against Watson Laboratories, Inc. in response to Watson’s ANDA regarding Ortho TriCyclen Lo.

In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE® patent that Janssen licenses from Synaptech, a four-day non-jury trial was held in the Federal District Court in Delaware in May 2007. On August 27, 2008, the court held that the patent was invalid because it was not enabled. Janssen and Synaptech have appealed the decision. Since the court’s decision, three generic companies have received final approvals for their products and two companies, Barr and Alphapharm (Mylan), have launched “at risk” pending appeal. Additional generic approvals and launches could occur at any time.

On August 13, 2008, the Company’s subsidiary OMJPI, and Synaptech filed suit in Federal District Court in Delaware against Sandoz, Inc. in response to Sandoz’s ANDA regarding RAZADYNE® tablets. Sandoz seeks to bring its generic version of RAZADYNE® to market, before expiration of the patent that OMJPI licenses from Synaptech, in December 2008. In light of the court’s decision in the actions against Barr and Alphapharm, it is expected that the court will enter judgment for Sandoz shortly.

In the action against Andrx with respect to its ANDA challenge to the CONCERTA® patents, a five-day non-jury trial was held in the Federal District Court in Delaware in December 2007. The Court has yet to issue its ruling in that action.

In the action against Sandoz with respect to its ANDA challenge to a RAZADYNE® ER patent that Janssen licenses from Synaptech, the action has been stayed pending the outcome of the appeal in the above litigation in Delaware Federal District Court. Sandoz originally challenged only one of two patents for RAZADYNE® ER, and certified that it will await expiration of the second patent in 2019 before marketing its generic version of RAZADYNE® ER. In April 2008, Sandoz notified Janssen that it has now challenged the second patent in its ANDA and seeks to market the product before that patent expires in 2019. An infringement action was brought against Sandoz based on the second patent in the District of New Jersey in June 2008.

In the action against Barr with respect to its ANDA challenge to the RAZADYNE® ER patent that Janssen licenses from Synaptech, the action was stayed pending the outcome in the above litigation against Barr in Delaware Federal District Court. In September 2008, the Delaware decision invalidating the patent resulted in entry of judgment for Barr on that patent. Litigation against Barr as to another patent regarding RAZADYNE® ER will proceed, but no stay of generic entry applies to Barr as to that patent.

McNEIL-PPC, Inc. filed suit in April 2008 in Federal District Court in New Jersey against Perrigo Company with respect to its ANDA regarding MONISTAT® 1 Combination Pack. In September 2008, a Joint Voluntary Stipulation of Dismissal was entered.

In the Ultracet actions, Ortho-McNeil filed suit against Kali/Par in 2002, separately against Caraco in 2004, and separately against Teva/Barr in 2004 based on the patent then in force. In October 2005, Caraco’s motion for summary judgment of non-infringement of the original patent was granted and subsequently affirmed by the Federal Circuit. In August 2006, the PTO granted a reissue patent. Ortho-McNeil thereafter amended its pending claims against Kali/Par and Teva/Barr to assert claim 6 of the reissue patent. Ortho-McNeil also brought a new lawsuit against Kali/Par, Caraco, and Teva/Barr based on other claims of the reissue patent. In April 2007, certain of Kali/Par's and Teva/Barr’s motions for summary judgment of invalidity of the original patent were granted. In July 2007 Kali/Par settled all pending claims, acknowledging that the asserted claims of the reissue patent are valid, enforceable, and infringed. Also in July 2007, Ortho-McNeil filed suit against Apotex on the reissue patent. In March 2008, Ortho-McNeil filed suit against Mylan and AlphaPharm on the reissue patent. In April 2008, Caraco’s motion for summary judgment of invalidity of the reissue patent was granted. The Mylan/AlphaPharm case was dismissed on collateral estoppel grounds in light of the summary judgment finding of invalidity of the reissue patent in the Caraco case, and Apotex has filed a motion for summary judgment on similar grounds. Ortho-McNeil intends to appeal the summary judgment decision invalidating the claims of the reissue patent.

In the action against Lupin Pharmaceuticals, Inc. (Lupin) regarding its ANDA concerning LEVAQUIN®, Lupin contends that the United States Patent and Trademark Office improperly granted a patent term extension to the patent that Ortho-McNeil licenses from Daiichi Pharmaceuticals, Inc. Lupin alleges that the active ingredient in LEVAQUIN® was the subject of prior marketing, and therefore was not eligible for the patent term extension. Lupin concedes validity and that its product would violate the patent if marketed prior to the expiration of the original patent term.

AVERAGE WHOLESALE PRICE (AWP) LITIGATION

Johnson & Johnson and several of its pharmaceutical subsidiaries, along with numerous other pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Most of these cases, both federal actions and state actions removed to federal court, have been consolidated for pre-trial purposes in a Multi-District Litigation (MDL) in Federal District Court in Boston, Massachusetts. The plaintiffs in these cases include classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP.

The MDL Court identified classes of Massachusetts-only private insurers providing “Medi-gap” insurance coverage and private payers for physician-administered drugs where payments were based on AWP (“Class 2” and “Class 3”), and a national class of individuals who made co-payments for physician-administered drugs covered by Medicare (“Class 1”). A trial of the two Massachusetts-only class actions concluded before the MDL Court in December 2006. In June 2007, the MDL Court issued post-trial rulings, dismissing the Johnson & Johnson defendants from the case regarding all claims of Classes 2 and 3, and subsequently of Class 1 as well. AWP cases brought by various Attorneys General are expected to be set for trial in 2009.

OTHER

In July 2003, Centocor Inc., a Johnson & Johnson subsidiary, received a request that it voluntarily provide documents and information to the criminal division of the U.S. Attorney’s Office, District of New Jersey, in connection with its investigation into various Centocor marketing practices. Subsequent requests for documents have been received from the U.S. Attorney’s Office. Both the Company and Centocor have responded to these requests for documents and information.

In December 2003, Ortho-McNeil received a subpoena from the U.S. Attorney’s Office in Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label marketing, of the drug TOPAMAX® (topiramate). Additional subpoenas for documents have been received, and current and former employees have testified before a grand jury. Discussions are underway in an effort to resolve this matter, but whether agreement can be reached and on what terms is uncertain.

In January 2004, Janssen received a subpoena from the Office of the Inspector General of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of, and clinical trials for, RISPERDAL® (risperidone) from 1997 to 2002. Documents subsequent to 2002 have also been requested. An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL® was received from the U.S. Attorney’s Office for the Eastern District of Pennsylvania in November 2005. Subpoenas seeking testimony from various witnesses before a grand jury have also been received. Janssen is cooperating in responding to these subpoenas.

In August 2004, Johnson & Johnson Health Care Systems, Inc. (HCS), a Johnson & Johnson subsidiary, received a subpoena from the Dallas, Texas U.S. Attorney’s Office seeking documents relating to the relationships between the group purchasing organization, Novation, and HCS and other Johnson & Johnson subsidiaries. The Company’s subsidiaries involved have responded to the subpoena.

In September 2004, Ortho Biotech Inc. (Ortho Biotech), received a subpoena from the U.S. Office of Inspector General’s Denver, Colorado field office seeking documents directed to sales and marketing of PROCRIT® (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S. Oncology Inc., a healthcare services network for oncologists. Ortho Biotech has responded to the subpoena.

In September 2004, plaintiffs in an employment discrimination litigation initiated against the Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were employed at any time from November 1997 to the present. Plaintiffs seek monetary damages for the period 1997 through the present (including punitive damages) and equitable relief. The Court denied plaintiffs’ class certification motion in December 2006 and their motion for reconsideration in April 2007. Plaintiffs sought to appeal these decisions and, in April 2008, the Court of Appeals ruled that plaintiffs’ appeal of the denial of class certification was untimely. Plaintiffs are now engaged in further discovery of individual plaintiffs’ claims.

In March 2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of New Jersey, seeking records concerning contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four other leading suppliers of hip and knee implants in late September 2007 by agreements with the U.S. Attorney’s Office for the District of New Jersey. The settlements include an 18-month Deferred Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the DPA and, with respect to four of the five companies, payment of settlement monies and entry into five year Corporate Integrity Agreements. DePuy paid $85 million as its settlement. In November 2007, the Attorney General of the Commonwealth of Massachusetts issued a civil investigative demand to DePuy seeking information regarding financial relationships between a number of Massachusetts-based orthopedic surgeons and providers and DePuy, which relationships had been publicly disclosed by DePuy pursuant to the DPA. In February 2008, DePuy received a written request for information from the U.S. Senate Special Committee on Aging, as a follow-up to earlier inquiries, concerning a number of aspects of the DPA.

In June 2005, the U.S. Senate Committee on Finance requested the Company to produce information regarding use by several of its pharmaceutical subsidiaries of educational grants. A similar request was sent to other major pharmaceutical companies. In July 2005, the Committee specifically requested information about educational grants in connection with the drug PROPULSID®. A follow up request was received from the Committee for additional information in January 2006. On October 30, 2007 another letter was received from the U.S. Senate Committee on Finance requesting information concerning payments to a list of physicians, and specification as to whether any such payments were for continuing medical education, honoraria, research support, etc. The Company has responded to these requests.

In July 2005, Scios Inc. (Scios), a Johnson & Johnson subsidiary, received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to the sales and marketing of NATRECOR®. Scios is responding to the subpoena. In early August 2005, Scios was advised that the investigation would be handled by the U.S. Attorney’s Office for the Northern District of California in San Francisco. Additional requests for documents have been received and responded to and former and current Scios employees have testified before a grand jury in San Francisco.

In September 2005, Johnson & Johnson received a subpoena from the U.S. Attorney’s Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. The Johnson & Johnson subsidiaries involved responded to the subpoena. Several employees of the Company’s pharmaceutical subsidiaries have been subpoenaed to testify before a grand jury in connection with this investigation.

In November 2005, Amgen filed suit against Hoffmann-LaRoche, Inc. in the U.S. District Court for the District of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it would seek to introduce into the United States, infringes a number of Amgen patents concerning EPO. Amgen licenses EPO for sale in the United States to Ortho Biotech for non-dialysis indications. Trial in this action concluded in October 2007 with a verdict in Amgen’s favor, finding the patents valid and infringed. The judge issued a preliminary injunction blocking the CERA launch, but said he was considering modifying that injunction to grant Roche a compulsory license that would allow it to launch in the U.S. if it paid a 22.5 percent royalty. Before the judge decided whether to grant Roche the compulsory license, however, Roche appealed the original granting of the preliminary injunction to the U.S. Court of Appeals for the Federal Circuit. In a subsequent decision, the district judge indicated he would not grant Roche a compulsory license.

In late December 2005 and early 2006, three purported class actions were filed on behalf of purchasers of endo-mechanical instruments against the Company and its wholly-owned subsidiaries, Ethicon, Inc., Ethicon Endo-Surgery, Inc., and Johnson & Johnson Health Care Systems, Inc. These cases challenge suture and endo-mechanical contracts with Group Purchasing Organizations and hospitals, in which discounts are predicated on a hospital achieving specified market share targets for both categories of products. These actions are in the process of being settled for approximately $14 million.

In February 2006, Johnson & Johnson received a subpoena from the U.S. Securities & Exchange Commission (SEC) requesting documents relating to the participation by several Johnson & Johnson subsidiaries in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and U.S. Department of Justice (DOJ) in producing responsive documents.

In September 2006, Janssen received a subpoena from the Attorney General of the State of California seeking documents regarding sales and marketing and side-effects of RISPERDAL®, as well as interactions with State officials regarding the State’s formulary for Medicaid-reimbursed drugs. Janssen has responded to the subpoena.

In February 2007, Johnson & Johnson voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries, which payments may fall within the jurisdiction of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the agencies, other issues potentially rising to the level of FCPA violations in additional markets have been brought to the attention of the agencies by the Company. The Company has provided and will continue to provide additional information to DOJ and SEC, and will cooperate with the agencies’ reviews of these matters. Law enforcement agencies of a number of other countries are also pursuing investigations of matters voluntarily disclosed by the Company to DOJ and SEC.

In March 2007, Cordis received a letter request for documents from the Committee on Oversight and Government Reform of the U.S. House of Representatives regarding marketing and safety of drug-eluting stents. Cordis has responded to the request.

In March 2007, the Company received separate subpoenas from the U.S. Attorney’s Office in Philadelphia, the U.S. Attorney’s Office in Boston and the U.S. Attorney’s Office in San Francisco. The subpoenas relate to investigations by these three offices referenced above concerning, respectively, sales and marketing of RISPERDAL® by Janssen, TOPAMAX® by Ortho-McNeil and NATRECOR® by Scios. The subpoenas request information regarding the Company’s corporate supervision and oversight of these three subsidiaries, including their sales and marketing of these drugs. The Company responded to these requests. In addition, the U.S. Attorney’s office in Boston has issued subpoenas for grand jury testimony to several employees of Johnson & Johnson.

In March 2007, the Company received a letter from the Committee on Energy and Commerce of the U.S. House of Representatives seeking answers to several questions regarding marketing and safety of PROCRIT®, the erythropoietin product sold by Ortho-Biotech. In March 2008, the Committee on Energy and Commerce sent the Company a second letter focused on direct-to-consumer advertising for PROCRIT®. In May 2007, Senator Grassley, the ranking member of the U.S. Senate Committee on Finance, sent the Company a letter seeking information relating to PROCRIT®. The Company provided its initial response in July 2007. By letter dated February 11, 2008, the Senate Finance Committee requested further rebate information for Ortho Biotech’s five largest physicians and/or group practices in each state. In May 2007, the New York State Attorney General issued a subpoena seeking information relating to PROCRIT®. Like the House and Senate requests, the subpoena asks for materials relating to PROCRIT® safety, marketing and pricing. The Company is responding to these requests.

In April 2007, the Company received two subpoenas from the Office of the Attorney General of the State of Delaware. The subpoenas seek documents and information relating to nominal pricing agreements. For purposes of the subpoenas, nominal pricing agreements are defined as agreements under which the Company agreed to provide a pharmaceutical product for less than ten percent of the Average Manufacturer Price for the product. The Company responded to these requests.

In August 2007, the Company received a request for documents and interviews of witnesses from the Committee on Energy and Commerce of the U.S. House of Representatives concerning GMP (Good Manufacturing Practice) issues involving the CYPHER® Stent. The letter states that FDA inspectors in 2003 identified “numerous systemic violations” of GMP’s in connection with CYPHER® manufacturing but nonetheless allowed Cordis to continue marketing CYPHER® Stents. Cordis has responded to this request.

In October 2007, the Company received a request for documents from Senator Grassley on behalf of the Committee on Finance of the U.S. Senate concerning continuing medical education payments to specific physicians. The Company responded to this request.

In November 2007, the Company received a request from United States Senators Byron Dorgan and Olympia Snowe seeking information relating to the Company’s oversight of foreign manufacturing facilities. The Company responded in January 2008.

In December 2007, the Company and its subsidiary Janssen received a request from Senator Grassley on behalf of the Committee on Finance of the U.S. Senate for documents and information concerning the marketing and promotion of RISPERDAL® for use by nursing home patients. The companies responded to this request.

In January 2008, the European Commission (“EC”) began an industry-wide antitrust inquiry concerning competitive conditions within the pharmaceutical sector. Because this is a sector inquiry, it is not based on any specific allegation that the company has violated EC competition law. The inquiry began with unannounced raids of a substantial number of pharmaceutical companies throughout Europe, including Johnson & Johnson affiliates. In March 2008, the EC issued detailed questionnaires to approximately 100 companies, including Johnson & Johnson affiliates.

In March 2008, the Company received a letter request from the Attorney General of the State of Michigan. The request seeks documents and information relating to nominal price transactions. The Company is responding to the request and will cooperate with the inquiry.

In June 2008, Johnson & Johnson received a subpoena from the United States Attorneys Office for the District of Massachusetts relating to the marketing of biliary stents by the company’s Cordis subsidiary. Cordis is cooperating in responding to the subpoena.

In September 2008, Multilan AG, an indirect subsidiary of Schering-Plough Corporation, commenced arbitration against Janssen Pharmaceutica NV for an alleged wrongful termination of an agreement relating to payments in connection with termination of certain marketing rights. Multilan seeks declaratory relief, specific performance and damages. Multilan alleges that damages exceed €700 million. The parties are in the process of selecting an arbitral tribunal.

On October 16, 2008, the Company received a letter from the Senate Committee on Finance and the Senate Subcommittee on Aging requesting information regarding the relationship between certain doctors and organizations and J&J, principally relating to the CYPHER® stent. The Company is in the process of responding to these inquiries.

On October 23, 2008, the Company received a letter from the Senate Committee on Finance requesting information on any payments or benefits to a number of specified psychiatrists associated with psychiatric professional associations or otherwise authorities in their field. The Company is in the process of responding to the request.

With respect to all the above matters, the Company and its subsidiaries are vigorously contesting the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of success. The Company and its subsidiaries involved in these matters continually evaluate their strategies in managing these matters and, where appropriate, pursue settlements and other resolutions where those are in the best interest of the Company.

The Company is also involved in a number of other patent, trademark and other lawsuits incidental to its business. The ultimate legal and financial liability of the Company in respect to all claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However, in the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position, although the resolution in any reporting period of one or more of these matters could have a significant impact on the Company’s results of operations and cash flows for that period.

NOTE 13 Fair Value Measurements

During the fiscal first quarter of 2008, the Company adopted SFAS No. 157, Fair Value Measurements, except for non-financial assets and liabilities recognized or disclosed at fair value on a non-recurring basis, for which the effective date is fiscal years beginning after November 15, 2008. SFAS No. 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. During the fiscal first quarter of 2008, the Company adopted SFAS No. 159, Fair Value Option for Financial Assets and Financial Liabilities. SFAS No. 159 permits the Company to measure certain financial assets and financial liabilities at fair value. The Company assessed the fair value option made available upon adopting SFAS No. 159, and has elected not to apply the fair value option to any financial instruments that were not already recognized at fair value.

SFAS No. 157 defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The statement establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with level 1 having the highest priority and level 3 having the lowest.

The following table provides a summary of the significant assets and liabilities that are measured at fair value as of September 28, 2008.

(Dollars in Millions)			Quoted prices in active markets for identical assets	Significant other observable inputs		Significant unobservable inputs
	September 28, 2008		Level 1	Level 2		Level 3
Assets
Derivative instruments	$	1,044		$	1,044

Liabilities
Derivative instruments	$	1,600		$	1,600

The Company uses forward exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes on future intercompany and third party purchases of raw materials denominated in foreign currency. The Company also uses currency swaps to manage currency risk primarily related to borrowings. The fair value of derivative instruments is the aggregation, by currency, of all future cash flows discounted to present value at prevailing market interest rates, and subsequently converted to the United States dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differs from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position.

The Company did not have any other significant financial assets or liabilities, which would require revised valuations under SFAS No. 157 that are recognized at fair value.

NOTE 14 Subsequent Events

On October 16, 2008 the Company completed the acquisition of SurgRx, Inc. SurgRx, Inc. is a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL® family of devices.

September 30, 2008, the district court entered judgments, including interest, in the amounts of $702 million and $521 million against Boston Scientific and Medtronic, respectively. Boston Scientific has appealed the judgment, but Medtronic paid $472 million in October 2008, representing the judgment, net of amounts exchanged in settlement of a number of other litigations between the companies.

October 27, 2008, the Company completed the acquisition of HealthMedia, Inc. a privately held company that creates web-based behavior change interventions.

Item 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

Analysis of Consolidated Sales

For the first fiscal nine months of 2008, worldwide sales were $48.6 billion, a total increase of 7.6% including an operational increase of 3.0% over 2007 first fiscal nine months sales of $45.1 billion. Currency had a positive impact of 4.6% for the period.

Sales by U.S. companies were $24.6 billion in the first fiscal nine months of 2008, which represented an increase of 1.8% over the same period last year. Sales by international companies were $23.9 billion, which represented a total increase of 14.3% including an operational increase of 4.3%, and a positive impact from currency of 10.0% over the first fiscal nine months of 2007.

Sales by companies in Europe achieved total growth of 12.6%, including an operational growth of 1.4% and a positive impact from currency of 11.2%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved total growth of 18.2% including operational growth of 8.4% and a positive impact from currency of 9.8%. Sales by companies in the Asia-Pacific, Africa region posted sales growth of 15.5%, with operational growth of 7.8% and a positive impact from currency of 7.7%.

For the fiscal third quarter of 2008, worldwide sales were $15.9 billion, a total increase of 6.4% and an operational increase of 3.3%, over 2007 fiscal third quarter sales of $15.0 billion. Currency fluctuations positively impacted sales by 3.1% for the period.

Sales by U.S. companies were $7.9 billion in the fiscal third quarter of 2008, which represented an increase of 0.4%. Sales by international companies were $8.0 billion, which represented a total increase of 13.1%, including an operational increase of 6.5%, and a positive impact from currency of 6.6% over the fiscal third quarter of 2007.

Sales by companies in Europe achieved total growth of 8.3%, with operational growth of 1.0% and a positive impact from currency of 7.3%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved total growth of 22.3%, operational growth of 15.3% and a positive impact from currency of 7.0%. Sales by companies in the Asia-Pacific, Africa region posted sales growth of 16.5%, with operational growth of 11.3% and a positive impact from currency of 5.2%.

Analysis of Sales by Business Segments

Consumer

Consumer segment sales in the first fiscal nine months of 2008 were $12.2 billion, an increase of 14.2% over the same period a year ago, with 8.7% of operational growth and a positive currency impact of 5.5%. U.S. Consumer segment sales increased by 10.5% while international sales achieved growth of 17.2%, representing an operational increase of 7.3%, with a positive currency impact of 9.9%.

Major Consumer Franchise Sales – First Fiscal Nine Months


(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
OTC Pharm & Nutr	$	4,438	$	3,727		19.1	%		14.2	%		4.9	%
Skin Care		2,537		2,258		12.4			6.9			5.5
Baby Care		1,691		1,445		17.0			9.8			7.2
Women’s Health		1,475		1,345		9.7			2.9			6.8
Oral Care		1,228		1,109		10.7			6.4			4.3
Wound Care/Other		830		799		3.9			(0.3	)		4.2
Total	$	12,199	$	10,683		14.2	%		8.7	%		5.5	%

Consumer segment sales in the fiscal third quarter of 2008 were $4.1 billion, an increase of 13.1% over the same period a year ago with 9.4% of operational growth and a positive currency impact of 3.7%. U.S. Consumer segment sales increased by 11.2% while international sales achieved growth of 14.7%, representing an operational increase of 8.1%, with a positive currency impact of 6.6%.

Major Consumer Franchise Sales – Fiscal Third Quarter


(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
OTC Pharm & Nutr	$	1,439	$	1,264		13.8	%		11.3	%		2.5	%
Skin Care		858		737		16.4			12.0			4.4
Baby Care		586		511		14.7			9.4			5.3
Women’s Health		510		461		10.6			5.5			5.1
Oral Care		434		396		9.6			6.7			2.9
Wound Care/Other		272		254		7.1			4.2			2.9
Total	$	4,099	$	3,623		13.1	%		9.4	%		3.7	%

The OTC Pharmaceuticals and Nutritionals franchise achieved operational growth of 11.3% over prior year fiscal third quarter. A major contributor was the continued success of over-the-counter ZYRTEC® in the U.S., which was launched during the fiscal first quarter of 2008. On October 7, 2008 the Company announced a voluntary labeling change on children’s cough and cold medicines regarding usage for children under the age of 4 years, to encourage the safe, effective use of these products. These actions will not have a significant impact on sales for the OTC Pharmaceuticals and Nutritionals franchise.

The Skin Care franchise achieved operational growth of 12.0% over prior year fiscal third quarter. Strong growth was driven by NEUTROGENA®, CLEAN & CLEAR®, AVEENO® and Johnson’s Adult product lines due to new product launches and strength in the core business. Additionally, newly acquired products from the acquisition of Beijing Dabao Cosmetics Co., Ltd. contributed to the growth in the fiscal third quarter.

The Baby Care franchise operational growth of 9.4% over prior year fiscal third quarter was the result of strong sales performance by wipes, haircare and powder product lines primarily in sales outside the U.S.

The Women’s Health franchise operational growth of 5.5% over the prior year fiscal third quarter was primarily due to the successful launch of new products in the U.S.

The Oral Care franchise operational growth of 6.7% was driven by the strong growth of LISTERINE® mouthwash. The launch of the dissolvable whitening strips in the third quarter of 2007 impacted the U.S. growth comparisons for the quarter.

Pharmaceutical

Pharmaceutical segment sales in the first fiscal nine months of 2008 were $18.9 billion, a total increase of 2.2% over the same period a year ago with an operational decline of 1.5% and an increase of 3.7% related to the positive impact of currency. The U.S. Pharmaceutical sales decreased by 2.2% over the same period a year ago. Total growth in international Pharmaceutical sales was 9.9%, an increase related to the positive impact of currency.

Major Pharmaceutical Product Revenues* – First Fiscal Nine Months

(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
REMICADE®	$	2,862	$	2,419		18.3	%		18.3	%		-	%
TOPAMAX®		2,051		1,801		13.9			12.1			1.8
PROCRIT®/EPREX®		1,900		2,257		(15.8	)		(19.8	)		4.0
RISPERDAL®/Risperidone		1,841		2,546		(27.7	)		(30.0	)		2.3
LEVAQUIN®/FLOXIN®		1,180		1,214		(2.8	)		(3.0	)		0.2
RISPERDAL® CONSTA®		990		833		18.8			11.2			7.6
CONCERTA®		967		739		30.9			27.3			3.6
ACIPHEX®/PARIET®		884		1,010		(12.5	)		(16.9	)		4.4
DURAGESIC®/Fentanyl Transdermal		764		900		(15.1	)		(21.0	)		5.9
Other		5,443		4,750		14.6			8.2			6.4
Total	$	18,882	$	18,469		2.2	%		(1.5	)%		3.7	%

*Prior year amounts have been reclassified to conform to current presentation.

Pharmaceutical segment sales in the fiscal third quarter of 2008 were $6.1 billion, a total increase of 0.2% over the same period a year ago with an operational decline of 2.5% and an increase of 2.7% related to the positive impact of currency. U.S. Pharmaceutical sales decreased by 6.0% over the same period a year ago. Total growth in international Pharmaceutical sales was 10.3%, representing an operational increase of 3.3% with a positive currency impact of 7.0%.

Major Pharmaceutical Product Revenues* – Fiscal Third Quarter

(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
REMICADE®	$	978	$	819		19.4	%		19.4	%		-	%
TOPAMAX®		728		613		18.8			17.6			1.2
PROCRIT®/EPREX®		619		682		(9.2	)		(11.9	)		2.7
CONCERTA®		398		231		72.3			66.4			5.9
RISPERDAL® CONSTA®		338		294		15.0			9.8			5.2
LEVAQUIN®/FLOXIN®		333		371		(10.2	)		(10.4	)		0.2
RISPERDAL®/Risperidone		320		831		(61.5	)		(63.0	)		1.5
ACIPHEX®/PARIET®		282		338		(16.6	)		(19.0	)		2.4
DURAGESIC®/Fentanyl Transdermal		259		309		(16.2	)		(20.7	)		4.5
Other		1,858		1,611		15.3			10.7			4.6
Total	$	6,113	$	6,099		0.2	%		(2.5	)%		2.7	%

*Prior year amounts have been reclassified to conform to current presentation.

REMICADE® (infliximab), a biologic approved for the treatment of Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis and use in the treatment of rheumatoid arthritis, achieved operational growth of 19.4% over prior year fiscal third quarter. The U.S. sales growth was driven by market growth. An increase in export sales is due to the increased demand outside the U.S. and customer production planning needs. REMICADE® is competing in a market which is experiencing increased competition due to new entrants and the expansion of indications for existing competitors.

TOPAMAX® (topiramate), which has been approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines, achieved strong operational growth of 17.6% as compared to prior year fiscal third quarter. The growth was primarily due to increases in the migraine category partially offset by generic competition in certain markets outside the U.S. The patent for TOPAMAX® (topiramate) in the U.S. expired in September 2008. In July 2008, the U.S. Food and Drug Administration (FDA) granted pediatric exclusivity for TOPAMAX®, which extends market exclusivity in the U.S. until March 2009. The expiration of a product patent or loss of market exclusivity is likely to result in a significant reduction in sales. In the first fiscal nine months of 2008, U.S. sales of TOPAMAX® were $1.7 billion.

PROCRIT® (Epoetin alfa)/EPREX® (Epoetin alfa) experienced an operational sales decline of 11.9%, as compared to prior year fiscal third quarter. The decline in PROCRIT® sales was due to the declining markets for Erythropoiesis Stimulating Agents (ESAs) in the U.S. Outside the U.S., new competition and label reviews have contributed to the lower sales results for EPREX®. Discussions with European regulators regarding changes to the label for ESAs, including EPREX®, are underway. The FDA issued an order requiring a labeling supplement making specific revisions to the label for ESAs, including PROCRIT®. The label for PROCRIT® was updated July 30, based on review of emerging safety data for the use of ESAs in patients with cancer.

CONCERTA® (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder, achieved operational sales growth of 66.4% over the fiscal third quarter of 2007. Sales results in the fiscal third quarter of 2008 were favorably impacted by approximately $135 million, related to a change in the estimate of accrued rebates. Of the $135 million, $115 million relates to amounts recorded in prior years. An additional contributor to the sales growth was market growth. Although the original CONCERTA® patent expired in 2004, the FDA has not approved any generic version that is substitutable for CONCERTA®. Two parties have filed Abbreviated New Drug Applications (ANDAs) for generic versions of CONCERTA®, which are pending and may be approved at any time.

RISPERDAL® CONSTA® (risperidone), a long acting injectable for the treatment of schizophrenia, achieved operational growth of 9.8% over the fiscal third quarter of 2007. Strong growth was due to a positive shift from oral to injectable therapies outside the U.S.

LEVAQUIN®(levofloxacin)/FLOXIN®, RISPERDAL®(risperidone), ACIPHEX®/PARIET® and DURAGESIC®/Fentanyl Transdermal (fentanyl transdermal system) experienced operational declines of 10.4%, 63.0%, 19.0% and 20.7% respectively, versus the prior year. Generic competition continued to negatively impact the sales of these products.

Market exclusivity for RISPERDAL® oral in the U.S. expired on June 29, 2008 and Janssen, a Johnson & Johnson subsidiary, launched an authorized generic version of RISPERDAL® oral on June 30, 2008. Loss of market exclusivity for the RISPERDAL® oral patent has resulted in a significant reduction in sales in the U.S.

In the fiscal third quarter of 2008, Other Pharmaceutical sales achieved operational growth of 10.7% versus the prior year. The biggest contributor to the increase was VELCADE®, a treatment for relapse multiple myeloma, which was co-developed with Millenium Pharmaceuticals, Inc.

Medical Devices and Diagnostics

Medical Devices and Diagnostics segment sales in the first fiscal nine months of 2008 were $17.5 billion, an increase of 9.4% over the same period a year ago, with 4.3% of this change due to operational increases and the remaining 5.1% increase related to the positive impact of currency. The U.S. Medical Devices and Diagnostics sales increase was 2.4% and the growth in international Medical Devices and Diagnostics sales was 16.0%, which included operational increases of 6.0% and an increase of 10.0% related to the positive impact of currency.

Major Medical Devices and Diagnostics Franchise Sales* – First Fiscal Nine Months

(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
DEPUY®	$	3,737	$	3,378		10.6	%		6.7	%		3.9	%
ETHICON ENDO-SURGERY®		3,169		2,770		14.4			8.7			5.7
ETHICON®		2,922		2,659		9.9			4.1			5.8
CORDIS®		2,413		2,557		(5.6	)		(10.7	)		5.1
Diabetes Care		1,956		1,730		13.1			7.6			5.5
Vision Care		1,898		1,643		15.5			9.6			5.9
ORTHO-CLINICAL DIAGNOSTICS®		1,389		1,249		11.2			6.6			4.6
Total	$	17,484	$	15,986		9.4	%		4.3	%		5.1	%

*Prior year amounts have been reclassified to conform to current presentation.

Medical Devices and Diagnostics segment sales in the fiscal third quarter of 2008 were $5.7 billion, an increase of 8.8% over the same period a year ago, with 5.6% of this change due to operational growth and the remaining 3.2% increase related to the positive impact of currency. The U.S. Medical Devices and Diagnostics sales increase was 3.1% and the growth in international Medical Devices and Diagnostics sales was 14.3%, which included operational growth of 8.0% and an increase of 6.3% related to the positive impact of currency.

Major Medical Devices and Diagnostics Franchise Sales* – Fiscal Third Quarter

(Dollars in Millions)	Sept. 28, 2008		Sept. 30, 2007		Total Change			Operations Change			Currency Change
DEPUY®	$	1,195	$	1,086		10.0	%		8.0	%		2.0	%
ETHICON ENDO-SURGERY®